In patients with inflammatory bowel diseases (IBD) who underwent colonoscopic surveillance for colorectal neoplasia (CRN), indefinite dysplasia was independently associated with a significant increase in advanced CRN risk.
Gastroenterology Advisor spoke to Dr. Robert McLean, President of the American College of Physicians (ACP), and Dr. Timothy Wilt, Chair of ACP’s Clinical Guidelines Committee to address several of these questions from the Colorectal Cancer Screening Guidance Statement.
A triplet combination of therapies results in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with the BRAF V600E mutation.
PDE5 inhibitor use was associated with a 35% decreased risk for CRC in male patients with a history of a benign colorectal neoplasm, and the decrease was associated with increasing cumulative dose of PDE5 inhibitors.
High-intensity surveillance after removal of adenoma provides modest incremental clinical benefits at an acceptable cost over return to routine screening or low-intensity surveillance and that current US recommendations for 5-year and 3-year surveillance following LRA removal and HRA removal, respectively, remain reasonable.
Survey results show level of concordance between patients with CRC and their caregivers when rating care quality. The survey also measured whether clinical or demographic factors influenced the agreement between patient-caregiver pairs.
The uptick in early-onset disease began in the mid-1990s among most high-income countries with long-term data. In younger adults, the steepest increases were seen in South Korea and New Zealand (average annual percent change, 4.2 and 4.0, respectively).
For patients with advanced/metastatic colorectal cancer (mCRC), greater total physical activity is not associated with longer overall survival, but it may prolong progression-free survival and lower the risk for treatment-related toxicities.